# Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

> **NCT05165433** · PHASE1 · COMPLETED · sponsor: **Akamis Bio** · enrollment: 14 (actual)

## Conditions studied

- Epithelial Tumor
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** NG-350A plus Pembrolizumab

## Key facts

- **NCT ID:** NCT05165433
- **Lead sponsor:** Akamis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2025-08-29
- **Final completion:** 2025-09-26
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165433, "Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05165433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*